VTYX Live signals | Maximize Profits with Getagraph.com

SELL 102733 min ago

@ $2.33

Issued: 14 Feb 2024 @ 09:30

Return: 74.25%

Previous signal: Feb 12 - 14:19

Previous signal: Buy

Return: -6.99 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders...

Stats
Today's Volume	560 416
Average Volume	4.02M
Market Cap	240.56M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $-0.670 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.230
ATR14	$0.00500 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-12	Subramaniam Somu	Sell	695 339	Common Stock
2024-04-12	Nsv Partners Iii Lp	Sell	695 339	Common Stock
2024-04-02	Krueger Christopher W	Sell	1 651	Common Stock
2024-04-02	Nuss John	Sell	1 651	Common Stock
2024-04-02	Mohan Raju	Sell	4 312	Common Stock

INSIDER POWER
-9.36
Last 100 transactions
Buy: 2 083 814 \| Sell: 2 354 020

Volume Correlation

Long: -0.27 (neutral)

Short: -0.19 (neutral)

Signal:(32.548) Neutral

Ventyx Biosciences, Inc. Correlation

10 Most Positive Correlations
SVRA	0.94
SY	0.936
IDCC	0.93
OVID	0.929
NVCN	0.929
HURC	0.926
OVLY	0.919
GPACU	0.919
VBOC	0.918
BYNOU	0.916

10 Most Negative Correlations
NAKD	-0.93
PRPH	-0.91
ORPH	-0.903
CHKEL	-0.902
CSSEP	-0.902
PROC	-0.9
ALXO	-0.898
HCAQ	-0.897
TRIT	-0.895
AHPI	-0.892

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ventyx Biosciences, Inc. Correlation - Currency/Commodity

-0.17
( neutral )

0.33
( neutral )

0.00
( neutral )

0.31
( neutral )

-0.13
( neutral )

0.35
( neutral )

Ventyx Biosciences, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-941 000 (0.00 %)
EPS:	$-3.30

Q4	2023
Revenue:	$0
Gross Profit:	$-403 000 (0.00 %)
EPS:	$-0.790

Q3	2023
Revenue:	$0
Gross Profit:	$-265 000 (0.00 %)
EPS:	$-0.920

Q2	2023
Revenue:	$0
Gross Profit:	$-139 000 (0.00 %)
EPS:	$-0.910

Financial Reports:

No articles found.

Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.